טוען...
In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma
Recently, two phase III studies of bevacizumab, an anti-angiogenic, for newly diagnosed glioblastoma (GBM) patients were released. While they were unable to statistically significantly demonstrate that bevacizumab in combination with other therapies increases the overall survival of GBM patients, th...
שמור ב:
| הוצא לאור ב: | J R Soc Interface |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The Royal Society
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4535409/ https://ncbi.nlm.nih.gov/pubmed/26202682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1098/rsif.2015.0388 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|